Okabe; Takayoshi

Patent Applications and Registrations

Patent applications and USPTO patent grants for Okabe; Takayoshi.The latest application filed is for "novel anthranilic acid-based compound, and pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same".

Company Profile

5.8.13

Okabe; Takayoshi - Tokyo JP
Okabe; Takayoshi - Bunkyo-ku Tokyo
OKABE; Takayoshi - Tsukuba-shi JP
Okabe; Takayoshi - Ibaraki JP
Okabe; Takayoshi - Tsukuba JP

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Ester compound and PIN1 inhibitor, inflammatory disease therapeutic, and colon cancer therapeutic in which said ester compound is used Grant 11,203,565 - Asano , et al. December 21, 2	2021-12-21
Therapeutic agent for fatty liver diseases and therapeutic agent for adiposity Grant 11,071,738 - Asano , et al. July 27, 2	2021-07-27
Novel Amide Compound, and Pin1 Inhibitor, Therapeutic Agent for Inflammatory Diseases and Therapeutic Agent for Cancer That Use the Same App 20200383987 - Asano; Tomoichiro ; et al.	2020-12-10
Therapeutic Agent for Fatty Liver Diseases and Therapeutic Agent for Adiposity App 20200383989 - Asano; Tomoichiro ; et al.	2020-12-10
Novel Anthranilic Acid-Based Compound, and Pin1 Inhibitor, Therapeutic Agent for Inflammatory Diseases and Therapeutic Agent for Cancer That Use the Same App 20200383967 - Asano; Tomoichiro ; et al.	2020-12-10
Thieno[2,3-b]pyridine derivative, quinoline derivative, and use thereof Grant 10,689,394 - Ichijo , et al.	2020-06-23
Novel Ester Compound And Pin1 Inhibitor, Inflammatory Disease Therapeutic, And Colon Cancer Therapeutic In Which Said Ester Comp App 20190382330 - Asano; Tomoichiro ; et al.	2019-12-19
THIENO[2,3-b]PYRIDINE DERIVATIVE AND QUINOLINE DERIVATIVE, AND USE THEREOF App 20190177336 - Ichijo; Hidenori ; et al.	2019-06-13
Fused pyrazole derivative having autotaxin inhibitory activity Grant 10,189,843 - Nagano , et al. Ja	2019-01-29
Pyrimidinone derivative having autotaxin-inhibitory activity Grant 10,183,949 - Nagano , et al. Ja	2019-01-22
Pyrimidinone Derivative Having Autotaxin-inhibitory Activity App 20170158704 - NAGANO; Tetsuo ; et al.	2017-06-08
Kinase Inhibitor App 20170145005 - NAGANO; Tetsuo ; et al.	2017-05-25
Fused Pyrazole Derivative Having Autotaxin Inhibitory Activity App 20160376278 - NAGANO; Tetsuo ; et al.	2016-12-29
Pulmonary Hypertension Treating Agent App 20160368895 - NAGANO; Tetsuo ; et al.	2016-12-22
Method For Detecting Fluorescence Or Absorbance, Method For Suppressing Background, Method For Measuring Adp, Method For Measuring Activity Of Adp-synthesizing Enzyme, And Method For Measuring Activity Of Glucosyltransferase App 20160289728 - KUMAGAI; Kazuo ; et al.	2016-10-06
8-substituted Imidazopyrimidinone Derivative Having Autotaxin Inhibitory Activity App 20160002247 - NAGANO; Tetsuo ; et al.	2016-01-07
Anticancer agent Grant 9,156,827 - Nagano , et al. October 13, 2	2015-10-13
Anticancer Agent App 20130102776 - Nagano; Tetsuo ; et al.	2013-04-25
Neuropeptide Y receptor antagonist Grant 6,258,837 - Fukami , et al. July 10, 2	2001-07-10

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.